Acurx Pharmaceuticals, Inc. - Common Stock (ACXP)
0.4501
-0.0099 (-2.15%)
Acurx Pharmaceuticals Inc is a biopharmaceutical company focused on developing novel antimicrobial therapies to combat bacterial infections, particularly those caused by antibiotic-resistant pathogens
The company is engaged in research and development of innovative drug candidates that address critical unmet medical needs in the treatment of serious infections. With a commitment to advancing therapeutic options, Acurx aims to improve patient outcomes through its proprietary drug formulations and scientific expertise. The company's efforts are geared toward not only treating existing infections but also preventing the spread of multidrug-resistant bacteria in healthcare settings.

Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · March 7, 2025

Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.
Via Chartmill · March 7, 2025

In today's session, there are notable price gaps in the US markets on Friday. Take a closer look at the stocks that are gap up and gap down.
Via Chartmill · March 7, 2025

Acurx Pharmaceuticals shares are trading lower by 30% during Friday's session. The company announced a $1.1 million registered direct offering.
Via Benzinga · March 7, 2025

As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via Chartmill · March 7, 2025

Via Benzinga · March 7, 2025

Via Benzinga · March 7, 2025

As Bitcoin (CRYPTO: BTC) hit a new all-time high of $98,310 on Thursday morning during European trading hours, he total net asset value of U.S. Bitcoin spot exchange-traded funds (ETFs) has exceeded $100 billion, a milestone achieved in just 10 months since their
Via Benzinga · November 21, 2024

ACXP stock results show that Acurx Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 9, 2024

Via Benzinga · July 18, 2024

Via Benzinga · May 21, 2024

ACXP stock results show that Acurx Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 15, 2024

Shares of Alcoa Corporation (NYSEAA) rose sharply in today’s pre-market trading after the company reported better-than-expected sales for its first quarter.
Via Benzinga · April 18, 2024

Via Benzinga · March 19, 2024

Via Benzinga · March 19, 2024

Via Benzinga · March 18, 2024

ACXP stock results show that Acurx Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · March 18, 2024

Companies Reporting Before The Bell • Niu Techs (NASDAQNIU) is expected to report earnings for its fourth quarter.
Via Benzinga · March 18, 2024

Via Benzinga · January 17, 2024

Shares of Airspan Networks Holdings Inc. (NASDAQMIMO) shares rose sharply during Wednesday’s session after the company announced a partnership with GCT Semiconductor to develop an RF module. Airspan Networks Holdings shares surged 381% to $0.3699 on Wednesday.
Via Benzinga · January 17, 2024

Acurx Pharmaceuticals' ibezapolstat outperforms vancomycin with a 94% eradication rate. Stay tuned for Q1 2024 updates on Extended Clinical Cure and microbiome data.
Via Benzinga · January 17, 2024

Via Benzinga · January 17, 2024

Via Benzinga · December 14, 2023